Syndax Poised for Strong 2025 Report Amid Breakout Cancer Drug Sales

NEW YORK, NY – February 19, 2026 – As Syndax Pharmaceuticals prepares to announce its fourth quarter and full-year 2025 financial results on February 26, the biopharmaceutical community is watching with keen interest. The upcoming report is expected to cap a transformational year for the company, marked by the wildly successful launches of two innovative cancer therapies, Revuforj® and Niktimvo™, which have reshaped its financial trajectory and solidified its position as a major player in the oncology market.

Syndax announced that its management will host a conference call and webcast at 4:30 p.m. ET on Thursday, February 26, to discuss the financial results and provide a comprehensive business update. For a company that has consistently surpassed expectations throughout 2025, the event is more than a routine disclosure; it's a platform to detail a remarkable growth story and lay out the strategy for sustaining momentum in a highly competitive sector.

A Year of Explosive Financial Growth

Syndax's financial performance in 2025 has been nothing short of stellar, driven by the commercialization of its new drugs. The company has demonstrated a clear and rapid path toward profitability, a rare feat in the biopharmaceutical industry. A review of its quarterly performance reveals a powerful growth narrative.

The year began with first-quarter total revenue of $34 million, primarily from the first full quarter of sales for Revuforj and a partial quarter for Niktimvo. This strong start was quickly eclipsed. By the second quarter, total revenue grew to $38.0 million, with the company’s collaboration revenue from Niktimvo jumping to $9.4 million as the drug became profitable for Syndax in its first full quarter on the market. The net loss per share also narrowed significantly, beating analyst expectations.

This trend continued into the third quarter, which company leadership described in their November report as a period of “remarkable commercial and pipeline execution.” Total revenue surged 21% over the prior quarter to $45.9 million, again narrowing the net loss to $0.70 per share, which was better than Wall Street had anticipated. The consistent outperformance set a high bar for the end of the year.

In a preliminary announcement in January 2026, Syndax revealed fourth-quarter and full-year highlights that suggest the growth is not just continuing but accelerating. The company projected approximately $100 million in combined net revenue for Q4, blowing past analyst consensus estimates of around $64 million. This includes approximately $44 million from Revuforj, a 38% increase from the third quarter, and an estimated $56 million in total net sales for Niktimvo. With a year-end cash position of approximately $394 million, management has repeatedly affirmed its belief that the company is fully funded through to profitability.

Revuforj and Niktimvo: The Dual Engines of Success

The financial success is rooted in the strong clinical and commercial performance of Syndax's two FDA-approved assets, which are rapidly becoming standards of care in their respective indications.

Revuforj® (revumenib), a novel menin inhibitor, has seen exceptional uptake since its launch in late 2024. Initially approved for relapsed/refractory (R/R) KMT2A-rearranged acute myeloid leukemia (AML), the drug’s sales ramp has been impressive, growing from $20 million in Q1 to a preliminary $44 million in Q4. Total prescriptions have climbed steadily, increasing by approximately 35% in the fourth quarter alone. The drug has already reached a quarter of the 2,000-patient annual market for its initial indication.

A pivotal moment came on October 24, 2025, when the FDA granted Revuforj an expanded approval for the treatment of R/R AML with an NPM1 mutation. This decision, which followed a Priority Review, is expected to significantly broaden the drug's market and “meaningfully accelerate” sales growth, according to past management commentary. The drug's therapeutic innovation was also recognized when it was named “Best New Drug” at the prestigious Scrip Awards 2025.

Niktimvo™ (axatilimab-csfr), co-commercialized with Incyte, has been equally successful. Targeting chronic graft-versus-host disease (cGVHD), the monoclonal antibody has seen robust adoption across U.S. bone marrow transplant centers. Total net sales, reported by Incyte, grew from $13.6 million in its first partial quarter to a preliminary $56 million in Q4 2025, putting its first-year sales trajectory in line with other major blockbusters in the space. For Syndax, which receives a 50% share of the net commercial profit, Niktimvo became a positive cash flow contributor in its first full quarter on the market, showcasing the power of its strategic partnership.

Beyond Commercialization: Expanding the Therapeutic Frontier

While investors celebrate the current commercial success, they will be listening closely on February 26 for updates on Syndax's strategy to expand the reach of its key assets. The company is aggressively advancing both Revuforj and Niktimvo into earlier lines of therapy and new indications, aiming to unlock what its leadership has termed “multi-billion-dollar potential.”

A key focus is the REVEAL-ND trial, a Phase 3 study evaluating Revuforj in combination with other agents for newly diagnosed AML patients with NPM1 or KMT2A mutations. Success in this trial could move Revuforj into a much larger frontline treatment setting. The company expects to complete enrollment by the end of 2025, with topline data anticipated in the second half of 2026.

For Niktimvo, Syndax and its partners are exploring its potential beyond cGVHD. A Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), a debilitating lung disease, is already underway. Data presented at major medical conferences like the ASH Annual Meeting have continued to reinforce Niktimvo’s profile, highlighting its potential for long-term benefits and its tolerability, which could support its use in broader patient populations. The upcoming business update will be scrutinized for any new details on these pipeline expansion efforts, which represent the next wave of value creation for the company and its shareholders.